Lamivudine-resistant HIVM184V is durably suppressed with dolutegravir plus lamivudine dual therapy in humanised mice
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Date
2020Journal
Journal of Global Antimicrobial ResistancePublisher
Elsevier LtdType
Article
Metadata
Show full item recordSponsors
This work was supported by research funds from the Institute of Human Virology of the University of Maryland School of Medicine (Baltimore, MD, USA).Identifier to cite or link to this item
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85079846550&doi=10.1016%2fj.jgar.2020.01.018&partnerID=40&md5=99a344840e3339417d0a1a6a4a8c4de4; http://hdl.handle.net/10713/12158ae974a485f413a2113503eed53cd6c53
10.1016/j.jgar.2020.01.018
Scopus Count
Collections
Related articles
- Comparison of HIV-DNA decay in naive patients starting dolutegravir plus lamivudine or dolutegravir-based triple therapy.
- Authors: Lombardi F, Belmonti S, Borghetti A, Ciccullo A, Fabbiani M, Di Giambenedetto S
- Issue date: 2020 Sep 1
- Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial.
- Authors: Rojas J, de Lazzari E, Negredo E, Domingo P, Tiraboschi J, Ribera E, Abdulghani N, Puig J, Mateo MG, Podzamczer D, Gutierrez MM, Paredes R, Clotet B, Gatell JM, Blanco JL, Martínez E, DOLAM study group
- Issue date: 2021 Aug
- Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
- Authors: Santevecchi BA, Miller S, Childs-Kean LM
- Issue date: 2020 Dec
- Dolutegravir plus lamivudine for the treatment of HIV-1 infection.
- Authors: Ciccullo A, Baldin G, Borghetti A, Di Giambenedetto S
- Issue date: 2020 Apr